Adamas completed a Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine hydrochloride) extended-release capsules in patients with multiple sclerosis (MS) who have walking impairment. We plan to pursue a pivotal registration program for this indication.
Multiple sclerosis (MS) is a chronic autoimmune-mediated disorder that affects more than 2 million people worldwide and 400,000 people in the United States, where there are approximately 270,000 diagnosed and treated patients.
Multiple sclerosis disease manifests as unpredictable symptoms that can vary in severity and tend to progress over years, in some cases to near total disability. Walking impairment, which affects approximately 80 percent of diagnosed patients, is associated with an increased risk of falls and has a substantial impact on daily activities. Despite therapeutic advances, unmet medical needs remain for MS patients with walking impairment, including the need for a therapeutic agent that delivers an improvement in walking ability during the day.
~2 M people worldwide
~400,000 patients in U.S.
~270,000 diagnosed & treated